Pembrolizumab, an anti-programmed cell death protein 1 (PD-1), showed significantly longer progression-free survival than chemotherapy as a first-line treatment with fewer treatment-related side effects in patients with metastatic MSI-H/d-MMR colorectal cancer [16]. The gene discussed is PDCD1; the disease is colorectal cancer.